Wednesday 28 October 2015

Frequently Asked Analagesics & Antipyretics Objective Type Questions And Answers

91. Which of the following is an agonistantagonist type of opioid analgesic
(a) Pethidine
(b) Pentazocine
(c) Fentanyl
(d) Buprenorphine
Ans: B

92. Pentazocine differs from morphine in that
(a) It is inactive by the oral route
(b) It does not produce physical dependence
(c) It has a lower ceiling of analgesic effect
(d) Its action is not blocked by naloxone
Ans: C

93. Which action of morphine is incompletely reversed by naloxone ?
(a) Analgesia
(b) Respiratory depression
(c) Sedation
(d) Miosis
Ans: C

94. Lower dose of naloxone is required to
(a) Antagonise the actions of nalorphine
(b) Antagonise the actions of pentazocine
(c) Precipitate withdrawal in mildly morphine dependent subjects
(d) Precipitate withdrawal in highly morphine dependent subjects
Ans: D

95. Following mediators are involved in acute inflammation except
(a) Histamine
(b) Leukotrienes
(c) Interferons
(d) Bradykinin
Ans: C

96. The distinctive feature of the isoenzyme cyclooxygenase-2 is
(a) It is not inhibited by indomethacin
(b) It is inducible
(c) It generates cytoprotective prostagladins in gastric mucosa
(d) It is found only in foetal tissues
Ans: B

97. Aspirin produces analgesia by
(a) Preventing sensitization of peripheral pain receptors
(b) Affecting gating of pain impulses at spinal level
(c) Raising pain threshold at subcortical level
(d) Both (a) and (b)
Ans: D

98. Aspirin reduces fever by
(a) Decreasing heat production in the body
(b) Enhancing cutaneous blood flow
(c) Inducing sweating
(d) Both (b) and (c)
Ans: D

99. In the treatment of chronic inflammatory diseases, the most important limitation of aspirin is
(a) Acid – base and electrolytc disturbances
(b) Hypersensitivity and idiosyncratic reactions
(c) Gastric mucosal damage
(d) Salicylism
Ans: C

100. Generally the earliest manifestation of salicylism is
(a) Visual disturbance
(b) Excitement
(c) Hyperventillation
(d) Tinnitus
Ans: D

More Questions & Answers:-
Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9  
Page10

No comments:

Post a Comment